CN110305874A - Gerbil immunoglobulin IgG1, IgG2 recombinant protein, gene and application thereof - Google Patents
Gerbil immunoglobulin IgG1, IgG2 recombinant protein, gene and application thereof Download PDFInfo
- Publication number
- CN110305874A CN110305874A CN201910533984.2A CN201910533984A CN110305874A CN 110305874 A CN110305874 A CN 110305874A CN 201910533984 A CN201910533984 A CN 201910533984A CN 110305874 A CN110305874 A CN 110305874A
- Authority
- CN
- China
- Prior art keywords
- gerbil
- clawed
- igg2
- recombinant protein
- long
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000699694 Gerbillinae Species 0.000 title claims abstract description 81
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims abstract description 43
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims abstract description 43
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 28
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 18
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000002773 nucleotide Substances 0.000 claims abstract description 12
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 12
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims abstract description 10
- 238000001514 detection method Methods 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 239000000427 antigen Substances 0.000 claims abstract description 4
- 102000036639 antigens Human genes 0.000 claims abstract description 4
- 108091007433 antigens Proteins 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 6
- 239000013613 expression plasmid Substances 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 241001429382 Coxsackievirus A16 Species 0.000 description 3
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- OSRZOHXQCUFIQG-FPMFFAJLSA-N Ala-Phe-Pro Chemical compound C([C@H](NC(=O)[C@@H]([NH3+])C)C(=O)N1[C@H](CCC1)C([O-])=O)C1=CC=CC=C1 OSRZOHXQCUFIQG-FPMFFAJLSA-N 0.000 description 2
- ZXCAQANTQWBICD-DCAQKATOSA-N Cys-Lys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N ZXCAQANTQWBICD-DCAQKATOSA-N 0.000 description 2
- CSMHMEATMDCQNY-DZKIICNBSA-N Gln-Val-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CSMHMEATMDCQNY-DZKIICNBSA-N 0.000 description 2
- CVPXINNKRTZBMO-CIUDSAMLSA-N Glu-Arg-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)CN=C(N)N CVPXINNKRTZBMO-CIUDSAMLSA-N 0.000 description 2
- GYCPQVFKCPPRQB-GUBZILKMSA-N Glu-Gln-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N GYCPQVFKCPPRQB-GUBZILKMSA-N 0.000 description 2
- ZIYGTCDTJJCDDP-JYJNAYRXSA-N Glu-Phe-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZIYGTCDTJJCDDP-JYJNAYRXSA-N 0.000 description 2
- ZALGPUWUVHOGAE-GVXVVHGQSA-N Glu-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZALGPUWUVHOGAE-GVXVVHGQSA-N 0.000 description 2
- RGPWUJOMKFYFSR-QWRGUYRKSA-N His-Gly-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O RGPWUJOMKFYFSR-QWRGUYRKSA-N 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 108010065920 Insulin Lispro Proteins 0.000 description 2
- 241000699684 Meriones unguiculatus Species 0.000 description 2
- XKJUFUPCHARJKX-UWVGGRQHSA-N Met-Gly-His Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 XKJUFUPCHARJKX-UWVGGRQHSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- BWTKUQPNOMMKMA-FIRPJDEBSA-N Phe-Ile-Phe Chemical compound C([C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 BWTKUQPNOMMKMA-FIRPJDEBSA-N 0.000 description 2
- SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 2
- KWMUAKQOVYCQJQ-ZPFDUUQYSA-N Pro-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@@H]1CCCN1 KWMUAKQOVYCQJQ-ZPFDUUQYSA-N 0.000 description 2
- VWHJZETTZDAGOM-XUXIUFHCSA-N Pro-Lys-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VWHJZETTZDAGOM-XUXIUFHCSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DSLHSTIUAPKERR-XGEHTFHBSA-N Thr-Cys-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O DSLHSTIUAPKERR-XGEHTFHBSA-N 0.000 description 2
- DIPIPFHFLPTCLK-LOKLDPHHSA-N Thr-Gln-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O DIPIPFHFLPTCLK-LOKLDPHHSA-N 0.000 description 2
- WRQLCVIALDUQEQ-UNQGMJICSA-N Thr-Phe-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WRQLCVIALDUQEQ-UNQGMJICSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- RKIGNDAHUOOIMJ-BQFCYCMXSA-N Val-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 RKIGNDAHUOOIMJ-BQFCYCMXSA-N 0.000 description 2
- YTNGABPUXFEOGU-SRVKXCTJSA-N Val-Pro-Arg Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O YTNGABPUXFEOGU-SRVKXCTJSA-N 0.000 description 2
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 108010009298 lysylglutamic acid Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 108010004914 prolylarginine Proteins 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- HQJKCXHQNUCKMY-GHCJXIJMSA-N Ala-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C)N HQJKCXHQNUCKMY-GHCJXIJMSA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- DFCIPNHFKOQAME-FXQIFTODSA-N Arg-Ala-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O DFCIPNHFKOQAME-FXQIFTODSA-N 0.000 description 1
- CPSHGRGUPZBMOK-CIUDSAMLSA-N Arg-Asn-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CPSHGRGUPZBMOK-CIUDSAMLSA-N 0.000 description 1
- PNQWAUXQDBIJDY-GUBZILKMSA-N Arg-Glu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNQWAUXQDBIJDY-GUBZILKMSA-N 0.000 description 1
- PBSOQGZLPFVXPU-YUMQZZPRSA-N Arg-Glu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PBSOQGZLPFVXPU-YUMQZZPRSA-N 0.000 description 1
- HPSVTWMFWCHKFN-GARJFASQSA-N Arg-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O HPSVTWMFWCHKFN-GARJFASQSA-N 0.000 description 1
- PDQBXRSOSCTGKY-ACZMJKKPSA-N Asn-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N PDQBXRSOSCTGKY-ACZMJKKPSA-N 0.000 description 1
- APHUDFFMXFYRKP-CIUDSAMLSA-N Asn-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N APHUDFFMXFYRKP-CIUDSAMLSA-N 0.000 description 1
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 1
- GZXOUBTUAUAVHD-ACZMJKKPSA-N Asn-Ser-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GZXOUBTUAUAVHD-ACZMJKKPSA-N 0.000 description 1
- CPYHLXSGDBDULY-IHPCNDPISA-N Asn-Trp-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O CPYHLXSGDBDULY-IHPCNDPISA-N 0.000 description 1
- RDRMWJBLOSRRAW-BYULHYEWSA-N Asp-Asn-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O RDRMWJBLOSRRAW-BYULHYEWSA-N 0.000 description 1
- DGKCOYGQLNWNCJ-ACZMJKKPSA-N Asp-Glu-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O DGKCOYGQLNWNCJ-ACZMJKKPSA-N 0.000 description 1
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 1
- GWOVSEVNXNVMMY-BPUTZDHNSA-N Asp-Trp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)O)N GWOVSEVNXNVMMY-BPUTZDHNSA-N 0.000 description 1
- GGBQDSHTXKQSLP-NHCYSSNCSA-N Asp-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N GGBQDSHTXKQSLP-NHCYSSNCSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- DLOHWQXXGMEZDW-CIUDSAMLSA-N Gln-Arg-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O DLOHWQXXGMEZDW-CIUDSAMLSA-N 0.000 description 1
- DHNWZLGBTPUTQQ-QEJZJMRPSA-N Gln-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N DHNWZLGBTPUTQQ-QEJZJMRPSA-N 0.000 description 1
- AQPZYBSRDRZBAG-AVGNSLFASA-N Gln-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N AQPZYBSRDRZBAG-AVGNSLFASA-N 0.000 description 1
- UWMDGPFFTKDUIY-HJGDQZAQSA-N Gln-Pro-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O UWMDGPFFTKDUIY-HJGDQZAQSA-N 0.000 description 1
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 1
- CBOVGULVQSVMPT-CIUDSAMLSA-N Glu-Pro-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O CBOVGULVQSVMPT-CIUDSAMLSA-N 0.000 description 1
- UDEPRBFQTWGLCW-CIUDSAMLSA-N Glu-Pro-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O UDEPRBFQTWGLCW-CIUDSAMLSA-N 0.000 description 1
- TZOVVRJYUDETQG-RCOVLWMOSA-N Gly-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN TZOVVRJYUDETQG-RCOVLWMOSA-N 0.000 description 1
- KTSZUNRRYXPZTK-BQBZGAKWSA-N Gly-Gln-Glu Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KTSZUNRRYXPZTK-BQBZGAKWSA-N 0.000 description 1
- BEQGFMIBZFNROK-JGVFFNPUSA-N Gly-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)O BEQGFMIBZFNROK-JGVFFNPUSA-N 0.000 description 1
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 1
- ZLCLYFGMKFCDCN-XPUUQOCRSA-N Gly-Ser-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)CN)C(O)=O ZLCLYFGMKFCDCN-XPUUQOCRSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- WMKXFMUJRCEGRP-SRVKXCTJSA-N His-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N WMKXFMUJRCEGRP-SRVKXCTJSA-N 0.000 description 1
- DBXXASNNDTXOLU-MXAVVETBSA-N Ile-Leu-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DBXXASNNDTXOLU-MXAVVETBSA-N 0.000 description 1
- XDUVMJCBYUKNFJ-MXAVVETBSA-N Ile-Lys-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N XDUVMJCBYUKNFJ-MXAVVETBSA-N 0.000 description 1
- SAEWJTCJQVZQNZ-IUKAMOBKSA-N Ile-Thr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SAEWJTCJQVZQNZ-IUKAMOBKSA-N 0.000 description 1
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
- CLVUXCBGKUECIT-HJGDQZAQSA-N Leu-Asp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CLVUXCBGKUECIT-HJGDQZAQSA-N 0.000 description 1
- FZMNAYBEFGZEIF-AVGNSLFASA-N Leu-Met-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(=O)O)N FZMNAYBEFGZEIF-AVGNSLFASA-N 0.000 description 1
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- LJBVRCDPWOJOEK-PPCPHDFISA-N Leu-Thr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LJBVRCDPWOJOEK-PPCPHDFISA-N 0.000 description 1
- QUCDKEKDPYISNX-HJGDQZAQSA-N Lys-Asn-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QUCDKEKDPYISNX-HJGDQZAQSA-N 0.000 description 1
- GKFNXYMAMKJSKD-NHCYSSNCSA-N Lys-Asp-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O GKFNXYMAMKJSKD-NHCYSSNCSA-N 0.000 description 1
- XNKDCYABMBBEKN-IUCAKERBSA-N Lys-Gly-Gln Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O XNKDCYABMBBEKN-IUCAKERBSA-N 0.000 description 1
- RFQATBGBLDAKGI-VHSXEESVSA-N Lys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCCN)N)C(=O)O RFQATBGBLDAKGI-VHSXEESVSA-N 0.000 description 1
- YSPZCHGIWAQVKQ-AVGNSLFASA-N Lys-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN YSPZCHGIWAQVKQ-AVGNSLFASA-N 0.000 description 1
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 1
- VHTOGMKQXXJOHG-RHYQMDGZSA-N Lys-Thr-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O VHTOGMKQXXJOHG-RHYQMDGZSA-N 0.000 description 1
- OBPCXINRFKHSRY-SDDRHHMPSA-N Met-Met-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N OBPCXINRFKHSRY-SDDRHHMPSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- SCKXGHWQPPURGT-KKUMJFAQSA-N Phe-Lys-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O SCKXGHWQPPURGT-KKUMJFAQSA-N 0.000 description 1
- YDUGVDGFKNXFPL-IXOXFDKPSA-N Phe-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O YDUGVDGFKNXFPL-IXOXFDKPSA-N 0.000 description 1
- KPDRZQUWJKTMBP-DCAQKATOSA-N Pro-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 KPDRZQUWJKTMBP-DCAQKATOSA-N 0.000 description 1
- XUSDDSLCRPUKLP-QXEWZRGKSA-N Pro-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 XUSDDSLCRPUKLP-QXEWZRGKSA-N 0.000 description 1
- JFNPBBOGGNMSRX-CIUDSAMLSA-N Pro-Gln-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O JFNPBBOGGNMSRX-CIUDSAMLSA-N 0.000 description 1
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 1
- ZLXKLMHAMDENIO-DCAQKATOSA-N Pro-Lys-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLXKLMHAMDENIO-DCAQKATOSA-N 0.000 description 1
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- WKLJLEXEENIYQE-SRVKXCTJSA-N Ser-Cys-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O WKLJLEXEENIYQE-SRVKXCTJSA-N 0.000 description 1
- ULVMNZOKDBHKKI-ACZMJKKPSA-N Ser-Gln-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ULVMNZOKDBHKKI-ACZMJKKPSA-N 0.000 description 1
- HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- WSTIOCFMWXNOCX-YUMQZZPRSA-N Ser-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N WSTIOCFMWXNOCX-YUMQZZPRSA-N 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- OCWWJBZQXGYQCA-DCAQKATOSA-N Ser-Lys-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O OCWWJBZQXGYQCA-DCAQKATOSA-N 0.000 description 1
- PTWIYDNFWPXQSD-GARJFASQSA-N Ser-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N)C(=O)O PTWIYDNFWPXQSD-GARJFASQSA-N 0.000 description 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 1
- VAIWUNAAPZZGRI-IHPCNDPISA-N Ser-Trp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CO)N VAIWUNAAPZZGRI-IHPCNDPISA-N 0.000 description 1
- DDPVJPIGACCMEH-XQXXSGGOSA-N Thr-Ala-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DDPVJPIGACCMEH-XQXXSGGOSA-N 0.000 description 1
- NRBUKAHTWRCUEQ-XGEHTFHBSA-N Thr-Cys-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(O)=O NRBUKAHTWRCUEQ-XGEHTFHBSA-N 0.000 description 1
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- OBAMASZCXDIXSS-SZMVWBNQSA-N Trp-Glu-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N OBAMASZCXDIXSS-SZMVWBNQSA-N 0.000 description 1
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 1
- SCZJKZLFSSPJDP-ACRUOGEOSA-N Tyr-Phe-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O SCZJKZLFSSPJDP-ACRUOGEOSA-N 0.000 description 1
- NHOVZGFNTGMYMI-KKUMJFAQSA-N Tyr-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NHOVZGFNTGMYMI-KKUMJFAQSA-N 0.000 description 1
- HZYOWMGWKKRMBZ-BYULHYEWSA-N Val-Asp-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HZYOWMGWKKRMBZ-BYULHYEWSA-N 0.000 description 1
- SCBITHMBEJNRHC-LSJOCFKGSA-N Val-Asp-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N SCBITHMBEJNRHC-LSJOCFKGSA-N 0.000 description 1
- JXGWQYWDUOWQHA-DZKIICNBSA-N Val-Gln-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N JXGWQYWDUOWQHA-DZKIICNBSA-N 0.000 description 1
- VCAWFLIWYNMHQP-UKJIMTQDSA-N Val-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N VCAWFLIWYNMHQP-UKJIMTQDSA-N 0.000 description 1
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 1
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 description 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
- ZLNYBMWGPOKSLW-LSJOCFKGSA-N Val-Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLNYBMWGPOKSLW-LSJOCFKGSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 1
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 108010000998 wheylin-2 peptide Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了长爪沙鼠免疫球蛋白IgG1、IgG2重组蛋白、基因及其应用。长爪沙鼠免疫球蛋白IgG1重组蛋白,包括长爪沙鼠免疫球蛋白IgG1重链恒定区CH2、CH3,和N端的组氨酸标签,氨基酸序列如SEQ ID No.3所示,核苷酸序列如SEQ ID No.2所示。长爪沙鼠免疫球蛋白IgG2重组蛋白,包括长爪沙鼠免疫球蛋白IgG2重链恒定区CH2、CH3,和N端的组氨酸标签,氨基酸序列如SEQ ID No.4所示,核苷酸序列如SEQ ID No.1所示。重组蛋白作为免疫抗原用于抗体制备,或者用于免疫检测。本发明所提供的重组蛋白与常规从沙鼠血清中分离纯化IgG相比具有特异性强、重复性好和纯度高等特点。
The invention discloses gerbil immunoglobulin IgG1, IgG2 recombinant protein, gene and application thereof. Clawed gerbil immunoglobulin IgG1 recombinant protein, including Clawed gerbil IgG1 heavy chain constant region CH2, CH3, and N-terminal histidine tag, the amino acid sequence is shown in SEQ ID No.3, nucleotide The sequence is shown as SEQ ID No.2. Clawed gerbil immunoglobulin IgG2 recombinant protein, including Clawed gerbil IgG2 heavy chain constant region CH2, CH3, and N-terminal histidine tag, the amino acid sequence is shown in SEQ ID No.4, nucleotide The sequence is shown as SEQ ID No.1. Recombinant proteins are used as immune antigens for antibody preparation, or for immune detection. Compared with conventionally isolated and purified IgG from gerbil serum, the recombinant protein provided by the present invention has the characteristics of strong specificity, good repeatability, high purity and the like.
Description
技术领域technical field
本发明属于生物技术领域,具体涉及一种长爪沙鼠免疫球蛋白IgG1和IgG2重链恒定区CH2和CH3重组蛋白的制备及其应用。The invention belongs to the field of biotechnology, and in particular relates to the preparation and application of a recombinant protein of heavy chain constant regions CH2 and CH3 of long-clawed gerbil immunoglobulin IgG1 and IgG2.
背景技术Background technique
长爪沙鼠(Meriones unguiculatus, Mongolian gerbil)大小介于大鼠和小鼠之间,在医学领域作为实验动物已有较长时间,它对多种病原易感,相比于其他啮齿类实验动物,长爪沙鼠对某些病原感染后可表现出与人类更相似的病理学特征和临床症状,因此近年来长爪沙鼠已越来越多地应用于多种微生物(细菌/病毒)和寄生虫感染等研究领域。然而,对于长爪沙鼠在病原感染后的免疫学指标尤其是特异性抗体血清学检测体系的建立尚有许多待完善之处。换而言之,外源病原感染长爪沙鼠后诱导产生的特异性抗体/免疫球蛋白(Immunoglobulin,Ig)如IgG或IgM的检测尚缺乏相应的特异性二抗即抗抗体,因而对长爪沙鼠免疫应答特别是体液免疫应答方面的研究受到了很大程度的限制。The gerbil (Meriones unguiculatus, Mongolian gerbil) is between the size of rats and mice. It has been used as an experimental animal in the medical field for a long time. It is susceptible to many pathogens. Compared with other rodent experimental animals The long-clawed gerbil can show pathological characteristics and clinical symptoms more similar to humans after being infected with certain pathogens. Therefore, in recent years, the long-clawed gerbil has been increasingly used in various microorganisms (bacteria/virus) and Research fields such as parasitic infection. However, there are still many things to be perfected for the establishment of immunological indicators of gerbils after pathogen infection, especially the establishment of specific antibody serological detection system. In other words, the detection of specific antibodies/immunoglobulins (Immunoglobulin, Ig) such as IgG or IgM induced by exogenous pathogens after infection of gerbils still lacks corresponding specific secondary antibodies, namely anti-antibodies. Research on the immune response of the gerbil, especially the humoral immune response, has been largely limited.
对长爪沙鼠抗体产生的检测最初(2002年)采用间接的凝集反应法和利用抗小鼠IgG多克隆抗体的酶联免疫吸附检测法(ELISA),因而可能影响实验结果的精确性和特异性。另一方面,近年来国内不同的研究组采用Protein G亲和层析纯化长爪沙鼠血清中的IgG,然后将其作为免疫原用于制备兔抗血清/多克隆抗体。长爪沙鼠血清中IgM 含量较其它动物高,而IgG 的含量并不高。由于Protein G也可以吸附长爪沙鼠血清中的其它抗体分子如IgM等,因而他们纯化获得的长爪沙鼠IgG中很可能夹杂含有其它抗体分子如IgM等。因此,他们制备的兔抗长爪沙鼠IgG多克隆抗体也很可能交叉识别长爪沙鼠其它抗体分子如IgM 等,从而造成其应用于下一步如ELISA等的实验结果偏差。The detection of antibody production in gerbils was initially (in 2002) using indirect agglutination reaction and enzyme-linked immunosorbent assay (ELISA) using anti-mouse IgG polyclonal antibody, which may affect the accuracy and specificity of the experimental results sex. On the other hand, in recent years, different domestic research groups have used Protein G affinity chromatography to purify IgG in gerbil serum, and then used it as an immunogen to prepare rabbit antiserum/polyclonal antibody. The content of IgM in the serum of gerbils is higher than that of other animals, but the content of IgG is not high. Since Protein G can also adsorb other antibody molecules such as IgM in the gerbil serum, the gerbil IgG they purified is likely to contain other antibody molecules such as IgM. Therefore, the rabbit anti-gerbil IgG polyclonal antibody prepared by them is also likely to cross-recognize other antibody molecules of gerbil such as IgM, which will cause deviation in the results of the next step such as ELISA.
Ukaji等测定了编码长爪沙鼠IgG1重链恒定区291个氨基酸和IgG2重链恒定区251个氨基酸的部分基因序列[Ukaji T,Exp Anim, 2012, 61(2):99-107;Ukaji T, Anim SciJ, 2011, 82(5):713-716.]。鼠类IgG重链恒定区蛋白/氨基酸序列比较分析表明长爪沙鼠IgG1重链恒定区和IgG2重链恒定区之间的同一性为72.4%,前者与小鼠IgG1重链恒定区的同一性最高为78.0%,而后者与仓鼠的IgG重链恒定区的同一性最高为84.6%。尽管长爪沙鼠IgG1和IgG2重链恒定区分别与小鼠IgG1、IgG2a、IgG2b、和IgG3重链恒定区具有67.0%~78.0%和78.1%~81.8%的同一性,但市售的兔或羊抗小鼠IgG多克隆抗体并不能交叉识别长爪沙鼠IgG[张锋,中国比较医学杂志,2017,27(1):37-42]。Ukaji et al. determined the partial gene sequence encoding 291 amino acids of the heavy chain constant region of the long-clawed gerbil IgG1 and 251 amino acids of the constant region of the IgG2 heavy chain [Ukaji T, Exp Anim, 2012, 61(2):99-107; Ukaji T , Anim SciJ, 2011, 82(5):713-716.]. The protein/amino acid sequence comparison analysis of murine IgG heavy chain constant region showed that the identity between the gerbil IgG1 heavy chain constant region and IgG2 heavy chain constant region was 72.4%, and the identity of the former with the mouse IgG1 heavy chain constant region The highest is 78.0%, and the latter has the highest identity of 84.6% with the IgG heavy chain constant region of hamster. Although the heavy chain constant regions of gerbil IgG1 and IgG2 are 67.0%-78.0% and 78.1%-81.8% identical to mouse IgG1, IgG2a, IgG2b, and IgG3 heavy chain constant regions, respectively, the commercially available rabbit or Goat anti-mouse IgG polyclonal antibody cannot cross-recognize gerbil IgG [Zhang Feng, Chinese Journal of Comparative Medicine, 2017, 27(1):37-42].
发明内容Contents of the invention
本发明针对现有技术的不足,提供了一种长爪沙鼠IgG1和IgG2重链恒定区CH2和CH3重组蛋白的制备及其应用。Aiming at the deficiencies of the prior art, the present invention provides preparation and application of a recombinant protein of heavy chain constant regions CH2 and CH3 of long-clawed gerbil IgG1 and IgG2.
一种长爪沙鼠免疫球蛋白IgG1重组蛋白的基因,包括长爪沙鼠免疫球蛋白IgG1重链恒定区CH2、CH3,和N端的组氨酸标签,核苷酸序列如SEQ ID No.1所示。A gene of recombinant protein of long-clawed gerbil IgG1 immunoglobulin, including CH2, CH3 of constant region of long-clawed immunoglobulin IgG1 heavy chain, and a histidine tag at N-terminal, the nucleotide sequence is as SEQ ID No.1 shown.
一种长爪沙鼠免疫球蛋白IgG1重组蛋白,包括长爪沙鼠免疫球蛋白IgG1重链恒定区CH2、CH3,和N端的组氨酸标签,氨基酸序列如SEQ ID No.3所示。A gerbil immunoglobulin IgG1 recombinant protein, including CH2, CH3, and N-terminal histidine tag of the heavy chain constant region of the gerbil IgG1 immunoglobulin, the amino acid sequence of which is shown in SEQ ID No.3.
一种长爪沙鼠免疫球蛋白IgG2重组蛋白的基因,包括长爪沙鼠免疫球蛋白IgG2重链恒定区CH2、CH3, 和N端的组氨酸标签,核苷酸序列如SEQ ID No.2所示。A gene of recombinant protein of long-clawed gerbil IgG2 immunoglobulin, including CH2, CH3 of heavy chain constant region of long-clawed immunoglobulin IgG2, and a histidine tag at N-terminal, the nucleotide sequence is as SEQ ID No.2 shown.
一种长爪沙鼠免疫球蛋白IgG2重组蛋白,包括长爪沙鼠免疫球蛋白IgG2重链恒定区CH2、CH3, 和N端的组氨酸标签,氨基酸序列如SEQ ID No.4所示。A gerbil immunoglobulin IgG2 recombinant protein, including CH2, CH3 of the heavy chain constant region of the gerbil IgG2 IgG2, and a histidine tag at the N-terminus, the amino acid sequence of which is shown in SEQ ID No.4.
一组长爪沙鼠免疫球蛋白IgG1和IgG2重组蛋白的基因,包括:长爪沙鼠免疫球蛋白IgG1重链恒定区CH2、CH3,和N端的组氨酸标签,核苷酸序列如SEQ ID No.1所示;长爪沙鼠免疫球蛋白IgG2重链恒定区CH2、CH3, 和N端的组氨酸标签,核苷酸序列如SEQ ID No.2所示。A set of genes for recombinant proteins of long-clawed gerbil IgG1 and IgG2, including: CH2, CH3, and N-terminal histidine tags of the heavy chain constant region of long-clawed gerbil IgG1 IgG, the nucleotide sequence of which is shown in SEQ ID Shown in No.1: CH2, CH3, and N-terminal histidine tag of the constant region of the IgG2 heavy chain of long-clawed gerbil IgG2, the nucleotide sequence is shown in SEQ ID No.2.
一组长爪沙鼠免疫球蛋白IgG1和IgG2重组蛋白,包括:长爪沙鼠免疫球蛋白IgG1重链恒定区CH2、CH3,和N端的组氨酸标签,氨基酸序列如SEQ ID No.3所示;长爪沙鼠免疫球蛋白IgG2重链恒定区CH2、CH3, 和N端的组氨酸标签,氨基酸序列如SEQ ID No.4所示。A group of long-clawed gerbil immunoglobulin IgG1 and IgG2 recombinant proteins, including: long-clawed gerbil IgG1 heavy chain constant region CH2, CH3, and N-terminal histidine tag, the amino acid sequence is as shown in SEQ ID No.3 Shown; the CH2, CH3, and N-terminal histidine tag of the heavy chain constant region of the long-clawed IgG2 immunoglobulin of gerbil, the amino acid sequence is shown in SEQ ID No.4.
所述的重组蛋白的应用,作为免疫抗原用于抗体制备,或者用于免疫检测。The application of the recombinant protein is used as an immune antigen for antibody preparation, or for immune detection.
所述的重组蛋白的基因的应用,克隆至表达质粒pET-28a(+)。The application of the gene of the recombinant protein is cloned into the expression plasmid pET-28a(+).
本发明的有益效果:Beneficial effects of the present invention:
将长爪沙鼠IgG1和IgG2重链恒定区CH2和CH3重组蛋白分别作为免疫原,制备得到了特异性多克隆抗体,可作为二抗用于酶联免疫吸附检测等用途。为长爪沙鼠特异性抗体血清学检测提供了有效工具,有助于长爪沙鼠作为实验动物的标准化和推广使用。The recombinant proteins of CH2 and CH3 in the heavy chain constant regions of gerbil IgG1 and IgG2 were respectively used as immunogens to prepare specific polyclonal antibodies, which can be used as secondary antibodies for enzyme-linked immunosorbent assays and other purposes. It provides an effective tool for the serological detection of the gerbil-specific antibody, and is helpful for the standardization and popularization of the gerbil as an experimental animal.
附图说明Description of drawings
图1为重组表达质粒编码示意图;Figure 1 is a schematic diagram of recombinant expression plasmid encoding;
图2为沙鼠IgG1CH23重组蛋白的表达与纯化产物电泳和Western印迹图;Fig. 2 is the expression of gerbil IgG1CH23 recombinant protein and purified product electrophoresis and Western blotting figure;
图3为沙鼠IgG2CH23重组蛋白的表达与纯化产物电泳图和Western印迹图;Fig. 3 is the expression and purification product electrophoresis picture and Western blotting picture of gerbil IgG2CH23 recombinant protein;
图4为兔抗沙鼠IgG1CH23和IgG2CH23多克隆抗体电泳图;Fig. 4 is the electrophoresis diagram of rabbit anti-gerbil IgG1CH23 and IgG2CH23 polyclonal antibody;
图5为兔抗沙鼠IgG1CH23和IgG2CH23多克隆抗体用于蛋白质印迹免疫技术(WB);Figure 5 is the rabbit anti-gerbil IgG1CH23 and IgG2CH23 polyclonal antibodies used in western blot immunotechnique (WB);
图6为兔抗沙鼠IgG1CH23和IgG2CH23多克隆抗体用于酶联免疫吸附检测(ELISA)。图中,1+2:一抗为沙鼠抗CVA16血清、二抗为HPP标记兔抗沙鼠IgG1CH23和IgG2CH23多克隆抗体;1:一抗为沙鼠抗CVA16血清、二抗为HPP标记兔抗沙鼠IgG1CH23多克隆抗体;2:一抗为沙鼠抗CVA16血清、二抗为HPP标记兔抗沙鼠IgG2CH23多克隆抗体;C:一抗为沙鼠未免疫血清对照、二抗为HPP标记兔抗沙鼠IgG1CH23和IgG2CH23多克隆抗体。Figure 6 shows the rabbit anti-gerbil IgG1CH23 and IgG2CH23 polyclonal antibodies used in enzyme-linked immunosorbent assay (ELISA). In the figure, 1+2: primary antibody is gerbil anti-CVA16 serum, secondary antibody is HPP-labeled rabbit anti-gerbil IgG1CH23 and IgG2CH23 polyclonal antibody; 1: primary antibody is gerbil anti-CVA16 serum, secondary antibody is HPP-labeled rabbit anti- Gerbil IgG1CH23 polyclonal antibody; 2: primary antibody is gerbil anti-CVA16 serum, secondary antibody is HPP-labeled rabbit anti-gerbil IgG2CH23 polyclonal antibody; C: primary antibody is gerbil non-immune serum control, secondary antibody is HPP-labeled rabbit Anti-gerbil IgG1CH23 and IgG2CH23 polyclonal antibodies.
具体实施方式Detailed ways
以下结合实施例和附图对本发明做进一步的阐述。The present invention will be further elaborated below in conjunction with the embodiments and the accompanying drawings.
重组蛋白,包括长爪沙鼠免疫球蛋白IgG1重链恒定区CH2、CH3或者IgG2重链恒定区CH2、CH3。上述重组蛋白是根据已报道的长爪沙鼠IgG1重链恒定区(GenBank序列号AB663132)和IgG2重链恒定区(GenBank序列号AB597231),选取其中的CH2和CH3区段。为了有利于重组蛋白在大肠杆菌中高效表达,将其对应的基因序列进行密码子优化并在N端与组氨酸(His)标签融合,克隆至表达质粒pET-28a(+)获得重组质粒pET-28a(+)-沙鼠IgG1CH23和pET-28a(+)-沙鼠IgG2-CH23,转化大肠杆菌BL21(DE3)感受态细胞,筛选获得转化子即重组表达菌。重组蛋白经诱导表达并纯化后,作为免疫原接种于兔子,获得抗血清后经亲和抗体层析柱纯化获得特异性多克隆抗体。Recombinant protein, including gerbil IgG1 heavy chain constant region CH2, CH3 or IgG2 heavy chain constant region CH2, CH3. The above recombinant protein is based on the reported CH2 and CH3 segments of the long-clawed gerbil IgG1 heavy chain constant region (GenBank sequence number AB663132) and IgG2 heavy chain constant region (GenBank sequence number AB597231). In order to facilitate the high-efficiency expression of the recombinant protein in E. coli, the corresponding gene sequence was codon-optimized and fused with a histidine (His) tag at the N-terminus, and cloned into the expression plasmid pET-28a(+) to obtain the recombinant plasmid pET -28a(+)-gerbil IgG1CH23 and pET-28a(+)-gerbil IgG2-CH23 were transformed into Escherichia coli BL21(DE3) competent cells, and the transformants were screened to obtain recombinant expression bacteria. After the recombinant protein was induced to express and purified, it was used as an immunogen to inoculate rabbits, and after obtaining antiserum, it was purified by affinity antibody chromatography to obtain specific polyclonal antibodies.
为了重组蛋白纯化的方便,可以使用亲和纯化标签。所述的重组蛋白包括组氨酸(His)标签序列。For the convenience of recombinant protein purification, affinity purification tags can be used. The recombinant protein includes a histidine (His) tag sequence.
所述的重组蛋白,长爪沙鼠免疫球蛋白IgG1重链恒定区CH2和CH3的氨基酸序列如SEQ ID No.3所示,核苷酸序列如SEQ ID No.1所示。The amino acid sequence of the recombinant protein, CH2 and CH3 of the heavy chain constant region of the gerbil IgG1 IgG1, is shown in SEQ ID No.3, and the nucleotide sequence is shown in SEQ ID No.1.
长爪沙鼠免疫球蛋白IgG2重链恒定区CH2和CH3的氨基酸序列如SEQ ID No.4所示,核苷酸序列如SEQ ID No.2所示。The amino acid sequence of CH2 and CH3 of the heavy chain constant region of the gerbil IgG2 IgG2 is shown in SEQ ID No.4, and the nucleotide sequence is shown in SEQ ID No.2.
实施例1 重组质粒pET-28a(+)-沙鼠IgG1CH23和pET-28a(+)-沙鼠IgG2-CH23的构建和转化Example 1 Construction and transformation of recombinant plasmids pET-28a(+)-gerbil IgG1CH23 and pET-28a(+)-gerbil IgG2-CH23
根据长爪沙鼠免疫球蛋白IgG1和IgG2重链恒定区的蛋白序列,选定它们各自的恒定域CH2和CH3,通过密码子优化后人工合成DNA片段,两端分别导入相应的限制性内切酶酶切位点NcoI和XhoI并克隆至大肠杆菌表达质粒pET-28a(+),使目的蛋白的N端带有His标签以利于纯化,获得相应的重组质粒经鉴定正确。重组表达质粒编码示意图如图1所示。According to the protein sequences of the heavy chain constant regions of the long-clawed gerbil immunoglobulin IgG1 and IgG2, select their respective constant domains CH2 and CH3, artificially synthesize DNA fragments after codon optimization, and introduce corresponding restriction endonucleases at both ends The NcoI and XhoI sites were digested with enzymes and cloned into the E. coli expression plasmid pET-28a(+), so that the N-terminus of the target protein was tagged with His to facilitate purification, and the corresponding recombinant plasmid was identified correctly. The schematic diagram of recombinant expression plasmid encoding is shown in Figure 1.
重组质粒pET-28a(+)-IgG1CH23表达沙鼠IgG1的恒定域CH2和CH3,编码218个氨基酸、理论分子量24.8 kDa;重组质粒pET-28a(+)-IgG2CH23表达沙鼠IgG2的恒定域CH2和CH3,编码187个氨基酸、理论分子量21.2 kDa。The recombinant plasmid pET-28a(+)-IgG1CH23 expresses the constant domains CH2 and CH3 of gerbil IgG1, encoding 218 amino acids and a theoretical molecular weight of 24.8 kDa; the recombinant plasmid pET-28a(+)-IgG2CH23 expresses the constant domains CH2 and CH3 of gerbil IgG2 CH3, encoding 187 amino acids, has a theoretical molecular weight of 21.2 kDa.
将重组质粒转化大肠杆菌BL21(DE3)感受态细胞,筛选获得转化子即重组表达菌。The recombinant plasmid was transformed into Escherichia coli BL21 (DE3) competent cells, and the transformants were screened to obtain recombinant expressing bacteria.
实施例2 长爪沙鼠IgG1-CH23和IgG2-CH23重组蛋白表达及纯化Example 2 Expression and purification of recombinant proteins of long-clawed gerbil IgG1-CH23 and IgG2-CH23
重组质粒pET-28a(+)-IgG1CH23和pET-28a(+)-IgG2-CH23分别转化大肠杆菌BL21(DE3)感受态细胞, 铺于LB平板37°C培养过夜,分别挑单菌落接种于LB液体培养基中,培养至吸光度A600达0.8后,加入IPTG(1 mmol/L)25°C诱导过夜。Recombinant plasmids pET-28a(+)-IgG1CH23 and pET-28a(+)-IgG2-CH23 were transformed into Escherichia coli BL21 (DE3) competent cells, spread on LB plates and cultured at 37°C overnight, and single colonies were picked and inoculated in LB In liquid medium, cultivate until the absorbance A 600 reaches 0.8, then add IPTG (1 mmol/L) to induce overnight at 25°C.
次日离心收集大肠杆菌菌体重悬于缓冲液后超声碎菌,离心收集上清和沉淀,用十二烷基磺酸钠聚丙烯酰胺凝胶电泳(SDS-PAGE)分析重组蛋白的表达形式。将破菌沉淀溶于含8mol/L脲液,离心后收集上清液,在变性条件下过His GravitrapTM柱,利用咪唑浓度梯度洗脱并收集目的蛋白,然后在透析液(10 mmol/L Tris,20 mmol/L NaCl [pH9.0])中4°C透析复性并逐步去除脲。The next day, Escherichia coli bacteria were collected by centrifugation, resuspended in buffer, and then ultrasonically crushed. The supernatant and precipitate were collected by centrifugation, and the expression form of the recombinant protein was analyzed by sodium dodecylsulfonate polyacrylamide gel electrophoresis (SDS-PAGE). Dissolve the broken bacteria pellet in 8 mol/L urea solution, collect the supernatant after centrifugation, pass through the His GravitrapTM column under denaturing conditions, use the imidazole concentration gradient to elute and collect the target protein, and then in the dialysate (10 mmol/L Tris , 20 mmol/L NaCl [pH9.0]) at 4°C for renaturation and gradual removal of urea.
沙鼠IgG1CH23重组蛋白的表达与纯化产物电泳和Western印迹图如图2所The expression and purification of the gerbil IgG1CH23 recombinant protein are shown in Figure 2 by electrophoresis and Western blot.
示,沙鼠IgG2CH23重组蛋白的表达与纯化产物电泳和Western印迹图如图3所示。Figure 3 shows the electrophoresis and Western blotting of the expression and purification product of the gerbil IgG2CH23 recombinant protein.
重组质粒分别转化大肠杆菌后,经IPTG诱导均可高效表达目的蛋白,都以包涵体形式存在并且分子量大小与预期相符。两者N端都引入了His标签以利于纯化,故WB均与抗His抗体呈特异性阳性反应。After the recombinant plasmids were transformed into Escherichia coli, the target protein could be highly expressed after being induced by IPTG, and all of them existed in the form of inclusion body and the molecular weight was in line with the expectation. A His tag was introduced into the N-terminus of both to facilitate purification, so WB showed specific positive reaction with anti-His antibody.
实施例3 兔抗长爪沙鼠IgG1-CH23和IgG2-CH23多克隆抗体的制备Example 3 Preparation of Rabbit Anti-Clawed Gerbil IgG1-CH23 and IgG2-CH23 Polyclonal Antibodies
将上述纯化的重组蛋白长爪沙鼠IgG1 CH23和IgG2 CH23分别作为免疫原接种于新西兰大耳白兔子,皮下多点注射,初次免疫四周后采血,分离血清并用Hitrap Protein A亲和抗体层析柱纯化获得多克隆抗体。The above-mentioned purified recombinant protein gerbil IgG1 CH23 and IgG2 CH23 were inoculated into New Zealand big-eared white rabbits respectively as immunogens, injected subcutaneously at multiple points, blood was collected four weeks after the initial immunization, serum was separated and used for Hitrap Protein A affinity antibody chromatography column Polyclonal antibodies were obtained by purification.
兔抗沙鼠IgG1CH23或IgG2CH23多克隆抗体电泳图如图4所示。The electropherogram of the rabbit anti-gerbil IgG1CH23 or IgG2CH23 polyclonal antibody is shown in Figure 4.
实施例4 兔抗长爪沙鼠IgG1 CH23和IgG2 CH23多克隆抗体用于蛋白质印迹免疫技术(WB)Example 4 Rabbit Anti-Clawed Gerbil IgG1 CH23 and IgG2 CH23 Polyclonal Antibody Used in Western Blot Immunotechnique (WB)
将上述兔抗长爪沙鼠IgG1 CH23和IgG2 CH23多克隆抗体分别用辣根过氧化物酶(HRP)标记后,用于蛋白质印迹免疫技术(WB)可以特异性地识别大肠杆菌表达的重组蛋白长爪沙鼠IgG1 CH23和IgG2 CH23(图5)。After the above rabbit anti-gerbil IgG1 CH23 and IgG2 CH23 polyclonal antibodies were labeled with horseradish peroxidase (HRP), the recombinant protein expressed in Escherichia coli can be specifically recognized by Western blot (WB) Gerbil IgG1 CH23 and IgG2 CH23 (Figure 5).
实施例5 兔抗长爪沙鼠IgG1 CH23和IgG2 CH23多克隆抗体用于酶联免疫吸附检测(ELISA)Example 5 Rabbit anti-gerbil IgG1 CH23 and IgG2 CH23 polyclonal antibodies used in enzyme-linked immunosorbent assay (ELISA)
将灭活的柯萨奇病毒A16型YY157株作为捕获抗原包被平板,长爪沙鼠抗CVA16血清或对照未免疫血清作为一抗,将HRP标记的兔抗长爪沙鼠IgG1 CH23和IgG2 CH23多克隆抗体作为二抗/抗IgG抗体用于ELISA,能检测柯萨奇病毒A16型(CAV16)感染长爪沙鼠后诱导产生的抗CAV16特异性IgG抗体(图6)。The inactivated Coxsackie virus A16 type YY157 strain was used as the capture antigen to coat the plate, the gerbil anti-CVA16 serum or the control non-immune serum was used as the primary antibody, and the HRP-labeled rabbit anti-gerbil IgG1 CH23 and IgG2 CH23 The polyclonal antibody was used as a secondary antibody/anti-IgG antibody in ELISA to detect the anti-CAV16-specific IgG antibody induced by Coxsackie virus A16 (CAV16) infection in gerbils (Figure 6).
上述实施例结果表明,采用分子克隆手段分别表达长爪沙鼠IgG1CH2和CH3重组蛋白和IgG2重链恒定域CH2和CH3重组蛋白,并作为免疫原成功制备获得了特异性兔多克隆抗体,为长爪沙鼠特异性抗体血清学检测提供了有效工具,有助于长爪沙鼠作为实验动物的标准化和推广使用。The results of the above examples show that the recombinant proteins of IgG1 CH2 and CH3 of long-clawed gerbils and the recombinant proteins of IgG2 heavy chain constant domain CH2 and CH3 were respectively expressed by means of molecular cloning, and specific rabbit polyclonal antibodies were successfully prepared as immunogens. The serological detection of gerbil-specific antibodies provides an effective tool and helps standardize and promote the use of gerbils as experimental animals.
序列表sequence listing
<110> 浙江省肿瘤医院<110> Zhejiang Cancer Hospital
<120> 长爪沙鼠免疫球蛋白IgG1、IgG2重组蛋白、基因及其应用<120> Gerbil immunoglobulin IgG1, IgG2 recombinant protein, gene and application thereof
<141> 2019-06-19<141> 2019-06-19
<160> 4<160> 4
<170> SIPOSequenceListing 1.0<170> SIPOSequenceListing 1.0
<210> 1<210> 1
<211> 665<211> 665
<212> DNA<212>DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 1<400> 1
ccatgggtca tcaccaccac catcacggcc tggttccgcg tggcagcgtg ccggaagttt 60ccatgggtca tcaccaccac catcacggcc tggttccgcg tggcagcgtg ccggaagttt 60
cttccgtgtt catctttcca ccgaaaccga aagatgttct gactatctcc ctgactccga 120cttccgtgtt catctttcca ccgaaaccga aagatgttct gactatctcc ctgactccga 120
agatcacctg cgtggtggtt gacatcagcc aggacgatcc agaggtggag atcagctggt 180agatcacctg cgtggtggtt gacatcagcc aggacgatcc agaggtggag atcagctggt 180
tcgttgacga tgtggaagta cacactgccc agacccagcc acgtgaagaa cagtttaact 240tcgttgacga tgtggaagta cacactgccc agacccagcc acgtgaagaa cagtttaact 240
ctactttccg tgtggtatcc accctgccga tcctgcacca ggactggctg aatggtaaag 300ctactttccg tgtggtatcc accctgccga tcctgcacca ggactggctg aatggtaaag 300
agttcaaatg caaagtgaac agcgaagcat ttccgagccc aatcgagaag accgtgagca 360agttcaaatg caaagtgaac agcgaagcat ttccgagccc aatcgagaag accgtgagca 360
agatgaaagg tcagccgcag gcaccgcagg tttacatgat gccaccaccg aaagagcaga 420agatgaaagg tcagccgcag gcaccgcagg tttacatgat gccaccaccg aaagagcaga 420
tgactaagaa cgaggtaact gtttcctgct acgttggcgg tttctatccg ccagatgttt 480tgactaagaa cgaggtaact gtttcctgct acgttggcgg tttctatccg ccagatgttt 480
ccgtagagtg gcagcgcaat ggcgagccgg aaccgaactt caaatctacc cagccgaccc 540ccgtagagtg gcagcgcaat ggcgagccgg aaccgaactt caaatctacc cagccgaccc 540
tggacactga cgagtcctac ttcctgtact ctaaactgga tgtaaagcgt gcaaactggg 600tggacactga cgagtcctac ttcctgtact ctaaactgga tgtaaagcgt gcaaactggg 600
agaaaggtga cgtgttcact tgctccgtgc tgcacgaggc actgcacaat catcactaac 660agaaaggtga cgtgttcact tgctccgtgc tgcacgaggc actgcacaat catcactaac 660
tcgag 665tcgag 665
<210> 2<210> 2
<211> 572<211> 572
<212> DNA<212>DNA
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 2<400> 2
ccatgggcca tcaccaccac catcacggtc tggttccgcg tggcagcgct ccagacctgt 60ccatgggcca tcaccaccac catcacggtc tggttccgcg tggcagcgct ccagacctgt 60
ctggcggtcc gtccgtgttt atcttcccac caaagccgaa agatgtgctg atgatgaccc 120ctggcggtcc gtccgtgttt atcttcccac caaagccgaa agatgtgctg atgatgaccc 120
tgactccgaa gatcacctgc gtggtagtag acgtttccga ggacgaaccg gatgttcagt 180tgactccgaa gatcacctgc gtggtagtag acgtttccga ggacgaaccg gatgttcagt 180
tcaactggtt cgttgacaat gtggaagtgc ataacgcgca gacccaaccg cgtgagggtc 240tcaactggtt cgttgacaat gtggaagtgc ataacgcgca gacccaaccg cgtgagggtc 240
agtacaactc taccttccgt gtagtgtctg cgctgccgat taagcaccaa gactggatgt 300agtacaactc taccttccgt gtagtgtctg cgctgccgat taagcaccaa gactggatgt 300
ctggcaaaga gttcaaatgc aaagttaaca acaaagcact gccgtctccg atcgagaaga 360ctggcaaaga gttcaaatgc aaagttaaca acaaagcact gccgtctccg atcgagaaga 360
ccatttccaa gccaaagggt ccggttcgtg agccgcaggt ttacgccttt ccaccaccga 420ccatttccaa gccaaagggt ccggttcgtg agccgcaggt ttacgccttt ccaccaccga 420
aggaacagat gaaccgtaac cagctgtctc tgacctgcat gattaccaac ttctatccgg 480aggaacagat gaaccgtaac cagctgtctc tgacctgcat gattaccaac ttctatccgg 480
aagcgatcga cgtggaatgg gaacgcaacg gccaggaaga gcgtaactac aagaacacca 540aagcgatcga cgtggaatgg gaacgcaacg gccaggaaga gcgtaactac aagaacacca 540
aaccagtgct ggattccgat ggctaactcg ag 572aaccagtgct ggattccgat ggctaactcg ag 572
<210> 3<210> 3
<211> 218<211> 218
<212> PRT<212> PRT
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 3<400> 3
Met Gly His His His His His His Gly Leu Val Pro Arg Gly Ser ValMet Gly His His His His His His His Gly Leu Val Pro Arg Gly Ser Val
1 5 10 151 5 10 15
Pro Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp ValPro Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val
20 25 30 20 25 30
Leu Thr Ile Ser Leu Thr Pro Lys Ile Thr Cys Val Val Val Asp IleLeu Thr Ile Ser Leu Thr Pro Lys Ile Thr Cys Val Val Val Asp Ile
35 40 45 35 40 45
Ser Gln Asp Asp Pro Glu Val Glu Ile Ser Trp Phe Val Asp Asp ValSer Gln Asp Asp Pro Glu Val Glu Ile Ser Trp Phe Val Asp Asp Val
50 55 60 50 55 60
Glu Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn SerGlu Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser
65 70 75 8065 70 75 80
Thr Phe Arg Val Val Ser Thr Leu Pro Ile Leu His Gln Asp Trp LeuThr Phe Arg Val Val Ser Thr Leu Pro Ile Leu His Gln Asp Trp Leu
85 90 95 85 90 95
Asn Gly Lys Glu Phe Lys Cys Lys Val Asn Ser Glu Ala Phe Pro SerAsn Gly Lys Glu Phe Lys Cys Lys Val Asn Ser Glu Ala Phe Pro Ser
100 105 110 100 105 110
Pro Ile Glu Lys Thr Val Ser Lys Met Lys Gly Gln Pro Gln Ala ProPro Ile Glu Lys Thr Val Ser Lys Met Lys Gly Gln Pro Gln Ala Pro
115 120 125 115 120 125
Gln Val Tyr Met Met Pro Pro Pro Lys Glu Gln Met Thr Lys Asn GluGln Val Tyr Met Met Pro Pro Pro Lys Glu Gln Met Thr Lys Asn Glu
130 135 140 130 135 140
Val Thr Val Ser Cys Tyr Val Gly Gly Phe Tyr Pro Pro Asp Val SerVal Thr Val Ser Cys Tyr Val Gly Gly Phe Tyr Pro Pro Asp Val Ser
145 150 155 160145 150 155 160
Val Glu Trp Gln Arg Asn Gly Glu Pro Glu Pro Asn Phe Lys Ser ThrVal Glu Trp Gln Arg Asn Gly Glu Pro Glu Pro Asn Phe Lys Ser Thr
165 170 175 165 170 175
Gln Pro Thr Leu Asp Thr Asp Glu Ser Tyr Phe Leu Tyr Ser Lys LeuGln Pro Thr Leu Asp Thr Asp Glu Ser Tyr Phe Leu Tyr Ser Lys Leu
180 185 190 180 185 190
Asp Val Lys Arg Ala Asn Trp Glu Lys Gly Asp Val Phe Thr Cys SerAsp Val Lys Arg Ala Asn Trp Glu Lys Gly Asp Val Phe Thr Cys Ser
195 200 205 195 200 205
Val Leu His Glu Ala Leu His Asn His HisVal Leu His Glu Ala Leu His Asn His His
210 215 210 215
<210> 4<210> 4
<211> 187<211> 187
<212> PRT<212> PRT
<213> 人工序列(Artificial Sequence)<213> Artificial Sequence
<400> 4<400> 4
Met Gly His His His His His His Gly Leu Val Pro Arg Gly Ser AlaMet Gly His His His His His His His Gly Leu Val Pro Arg Gly Ser Ala
1 5 10 151 5 10 15
Pro Asp Leu Ser Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys ProPro Asp Leu Ser Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Pro
20 25 30 20 25 30
Lys Asp Val Leu Met Met Thr Leu Thr Pro Lys Ile Thr Cys Val ValLys Asp Val Leu Met Met Thr Leu Thr Pro Lys Ile Thr Cys Val Val
35 40 45 35 40 45
Val Asp Val Ser Glu Asp Glu Pro Asp Val Gln Phe Asn Trp Phe ValVal Asp Val Ser Glu Asp Glu Pro Asp Val Gln Phe Asn Trp Phe Val
50 55 60 50 55 60
Asp Asn Val Glu Val His Asn Ala Gln Thr Gln Pro Arg Glu Gly GlnAsp Asn Val Glu Val His Asn Ala Gln Thr Gln Pro Arg Glu Gly Gln
65 70 75 8065 70 75 80
Tyr Asn Ser Thr Phe Arg Val Val Ser Ala Leu Pro Ile Lys His GlnTyr Asn Ser Thr Phe Arg Val Val Ser Ala Leu Pro Ile Lys His Gln
85 90 95 85 90 95
Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys AlaAsp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Ala
100 105 110 100 105 110
Leu Pro Ser Pro Ile Glu Lys Thr Ile Ser Lys Pro Lys Gly Pro ValLeu Pro Ser Pro Ile Glu Lys Thr Ile Ser Lys Pro Lys Gly Pro Val
115 120 125 115 120 125
Arg Glu Pro Gln Val Tyr Ala Phe Pro Pro Pro Lys Glu Gln Met AsnArg Glu Pro Gln Val Tyr Ala Phe Pro Pro Pro Lys Glu Gln Met Asn
130 135 140 130 135 140
Arg Asn Gln Leu Ser Leu Thr Cys Met Ile Thr Asn Phe Tyr Pro GluArg Asn Gln Leu Ser Leu Thr Cys Met Ile Thr Asn Phe Tyr Pro Glu
145 150 155 160145 150 155 160
Ala Ile Asp Val Glu Trp Glu Arg Asn Gly Gln Glu Glu Arg Asn TyrAla Ile Asp Val Glu Trp Glu Arg Asn Gly Gln Glu Glu Arg Asn Tyr
165 170 175 165 170 175
Lys Asn Thr Lys Pro Val Leu Asp Ser Asp GlyLys Asn Thr Lys Pro Val Leu Asp Ser Asp Gly
180 185 180 185
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910533984.2A CN110305874A (en) | 2019-06-19 | 2019-06-19 | Gerbil immunoglobulin IgG1, IgG2 recombinant protein, gene and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910533984.2A CN110305874A (en) | 2019-06-19 | 2019-06-19 | Gerbil immunoglobulin IgG1, IgG2 recombinant protein, gene and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110305874A true CN110305874A (en) | 2019-10-08 |
Family
ID=68076470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910533984.2A Pending CN110305874A (en) | 2019-06-19 | 2019-06-19 | Gerbil immunoglobulin IgG1, IgG2 recombinant protein, gene and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110305874A (en) |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1486192A (en) * | 2001-01-17 | 2004-03-31 | ��³�Ȱ�ҩƷ��˾ | Binding domain-immunoglobulin fusion proteins |
US6891024B2 (en) * | 2001-05-24 | 2005-05-10 | The Curators Of The University Of Missouri | Monoclonal antibodies to Sarcocystis neurona and uses therefor |
US20060148750A1 (en) * | 1999-12-22 | 2006-07-06 | Shiver John W | Polynucleotide vaccines expressing codon optimized HIV-1 Pol and modified HIV-1 Pol |
CN101258164A (en) * | 2005-08-16 | 2008-09-03 | 韩美药品工业株式会社 | Method for mass production of immunoglobulin Fc regions lacking an initial methionine residue |
AU2005201915B2 (en) * | 1999-05-28 | 2009-01-22 | Genentech, Inc. | DR4 antibodies and uses thereof |
CN101575379A (en) * | 2008-05-09 | 2009-11-11 | 上海中信国健药业有限公司 | Soluble VEGFR difunctional fusion receptors, preparation method and use thereof |
CN102036677A (en) * | 2008-03-20 | 2011-04-27 | 迈阿密大学 | Heat shock protein GP96 vaccination and methods of using same |
CN102175867A (en) * | 2010-12-23 | 2011-09-07 | 北京民海生物科技有限公司 | Enzyme-linked immunoassay kit for detecting rabies virus antibody |
CN103901202A (en) * | 2014-04-04 | 2014-07-02 | 中国人民解放军成都军区疾病预防控制中心 | Universal competitive ELISA detection method based on common epitope influenza A virus antibody |
US20140245468A1 (en) * | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
CN104076146A (en) * | 2014-06-19 | 2014-10-01 | 华北制药集团新药研究开发有限责任公司 | ELISA (Enzyme-Linked Immunosorbent Assay) kit for detecting human anti-rabies virus antibody |
CN104262488A (en) * | 2014-09-24 | 2015-01-07 | 普莱柯生物工程股份有限公司 | Preparation and application of fusion protein and vaccine composition thereof |
CN105137073A (en) * | 2015-08-06 | 2015-12-09 | 中国兽医药品监察所 | Bovine Brucella colloidal gold antibody detection test paper strip |
CN105759038A (en) * | 2016-04-15 | 2016-07-13 | 肖乐义 | Immunoassay method and kit for assaying mycobacterium tuberculosis from biological samples |
CN107011445A (en) * | 2007-06-01 | 2017-08-04 | 马里兰大学巴尔的摩分校 | Immunoglobulin constant region fc receptor binding agents |
US20170226162A1 (en) * | 2016-02-04 | 2017-08-10 | Trianni, Inc | Enhanced production of immunoglobulins |
CN107428830A (en) * | 2015-01-05 | 2017-12-01 | 依奈特制药公司 | Monomer FC domains |
CN108205063A (en) * | 2016-12-20 | 2018-06-26 | 浙江特瑞思药业股份有限公司 | The detection method of a kind of anti-CD-20 monoclonal antibody and antigen-binding activity (filter membrane plate ELISA) |
CN108226513A (en) * | 2016-12-15 | 2018-06-29 | 江苏维赛科技生物发展有限公司 | It is a kind of to detect the enzyme linked immunological kit that pseudo- cow's milk is mixed in buffalo's milk and sheep breast |
CN109180817A (en) * | 2018-09-19 | 2019-01-11 | 程晓东 | A kind of novel anti-human igg 1-Fc antibody reagent and preparation method thereof |
-
2019
- 2019-06-19 CN CN201910533984.2A patent/CN110305874A/en active Pending
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005201915B2 (en) * | 1999-05-28 | 2009-01-22 | Genentech, Inc. | DR4 antibodies and uses thereof |
US20060148750A1 (en) * | 1999-12-22 | 2006-07-06 | Shiver John W | Polynucleotide vaccines expressing codon optimized HIV-1 Pol and modified HIV-1 Pol |
CN1486192A (en) * | 2001-01-17 | 2004-03-31 | ��³�Ȱ�ҩƷ��˾ | Binding domain-immunoglobulin fusion proteins |
US6891024B2 (en) * | 2001-05-24 | 2005-05-10 | The Curators Of The University Of Missouri | Monoclonal antibodies to Sarcocystis neurona and uses therefor |
CN101258164A (en) * | 2005-08-16 | 2008-09-03 | 韩美药品工业株式会社 | Method for mass production of immunoglobulin Fc regions lacking an initial methionine residue |
CN107011445A (en) * | 2007-06-01 | 2017-08-04 | 马里兰大学巴尔的摩分校 | Immunoglobulin constant region fc receptor binding agents |
CN102036677A (en) * | 2008-03-20 | 2011-04-27 | 迈阿密大学 | Heat shock protein GP96 vaccination and methods of using same |
CN101575379A (en) * | 2008-05-09 | 2009-11-11 | 上海中信国健药业有限公司 | Soluble VEGFR difunctional fusion receptors, preparation method and use thereof |
CN102175867A (en) * | 2010-12-23 | 2011-09-07 | 北京民海生物科技有限公司 | Enzyme-linked immunoassay kit for detecting rabies virus antibody |
US20140245468A1 (en) * | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
CN103901202A (en) * | 2014-04-04 | 2014-07-02 | 中国人民解放军成都军区疾病预防控制中心 | Universal competitive ELISA detection method based on common epitope influenza A virus antibody |
CN104076146A (en) * | 2014-06-19 | 2014-10-01 | 华北制药集团新药研究开发有限责任公司 | ELISA (Enzyme-Linked Immunosorbent Assay) kit for detecting human anti-rabies virus antibody |
CN104262488A (en) * | 2014-09-24 | 2015-01-07 | 普莱柯生物工程股份有限公司 | Preparation and application of fusion protein and vaccine composition thereof |
CN107428830A (en) * | 2015-01-05 | 2017-12-01 | 依奈特制药公司 | Monomer FC domains |
CN105137073A (en) * | 2015-08-06 | 2015-12-09 | 中国兽医药品监察所 | Bovine Brucella colloidal gold antibody detection test paper strip |
US20170226162A1 (en) * | 2016-02-04 | 2017-08-10 | Trianni, Inc | Enhanced production of immunoglobulins |
CN105759038A (en) * | 2016-04-15 | 2016-07-13 | 肖乐义 | Immunoassay method and kit for assaying mycobacterium tuberculosis from biological samples |
CN108226513A (en) * | 2016-12-15 | 2018-06-29 | 江苏维赛科技生物发展有限公司 | It is a kind of to detect the enzyme linked immunological kit that pseudo- cow's milk is mixed in buffalo's milk and sheep breast |
CN108205063A (en) * | 2016-12-20 | 2018-06-26 | 浙江特瑞思药业股份有限公司 | The detection method of a kind of anti-CD-20 monoclonal antibody and antigen-binding activity (filter membrane plate ELISA) |
CN109180817A (en) * | 2018-09-19 | 2019-01-11 | 程晓东 | A kind of novel anti-human igg 1-Fc antibody reagent and preparation method thereof |
Non-Patent Citations (9)
Title |
---|
ALEXEY TEPLYAKOV等: "IgG2 Fc Structure and the Dynamic Features of the IgG CH2-CH3 Interface", 《MOL IMMUNOL》 * |
TAKAO UKAJI等: "Partial sequence of Mongolian gerbil (Meriones unguiculatus) immunoglobulin gamma heavy chain constant region", 《ANIMAL SCIENCE JOURNAL》 * |
TAKAO UKAJI等: "Sequence Determination of the Heavy-Chain Constant Region in Four Immunoglobulin Classes of Mongolian Gerbils (Meriones Unguiculatus)", 《EXPERIMENTAL ANIMALS》 * |
TIANLEI YING等: "Interactions of IgG1 CH2 and CH3 Domains With FcRn", 《FRONT IMMUNOL》 * |
刘亮伟等主编: "《基因工程原理与实验指导》", 30 September 2010, 中国轻工业出版社 * |
姜法铭等: "猪IgG H链基因CH2-CH3的克隆和分析", 《上海农业学报》 * |
李萍等: "HRP-SPA用于丙型肝炎检测 ", 《江苏大学学报(医学版)》 * |
陆曙梅: "《微生物学与免疫学基础》", 31 July 2007, 河南科学技术出版社 * |
顾青等主编: "《分子生物学实验指导》", 28 February 2014, 浙江工商大学出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Roden et al. | Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins | |
CN106220716B (en) | Infectious coryza of chicken subunit vaccine and preparation method thereof | |
AU2010323144B2 (en) | Monospecific polypeptide reagents | |
CN113527475B (en) | Hybridoma cell secreting novel duck reovirus sigma C protein monoclonal antibody, monoclonal antibody and application | |
CN113018427B (en) | Multivalent fusion protein vaccine based on neutralizing epitope of novel coronavirus | |
CN107033226B (en) | Peste des petits ruminants virus F protein epitope peptide, determination method, preparation method and application thereof | |
WO2023179588A1 (en) | Truncated varicella-zoster virus envelope glycoprotein ge | |
Piao et al. | Trigger factor assisted soluble expression of recombinant spike protein of porcine epidemic diarrhea virus in Escherichia coli | |
Yu et al. | Fine mapping and conservation analysis of linear B-cell epitopes of peste des petits ruminants virus hemagglutinin protein | |
CN110305874A (en) | Gerbil immunoglobulin IgG1, IgG2 recombinant protein, gene and application thereof | |
CN107033225B (en) | A kind of antigenic epitope peptide of peste des petits ruminants virus HN protein and its determination, preparation method and application | |
CN101696239A (en) | Human oocyte zona pellucida protein multi-epitope chimeric peptide antigen and preparation method thereof | |
CN113004386B (en) | Recombinant protein of grass carp anaphylatoxin C5a and its polyclonal antibody | |
CN109400684A (en) | A kind of PEDV S-RBD Linear B Cell Epitopes and two plants of specific recognition monoclonal antibodies and application | |
CN109504667B (en) | IRAK-M polyclonal antibody and preparation method thereof | |
KR102259974B1 (en) | Method for producing target antigen-specific antibody using recombinant antigen | |
CN111925447B (en) | A kind of human mouse egg zona pellucida fusion protein and its preparation method and application | |
Peng et al. | High variability in the N terminus of coat protein among potyviruses and its advantage in producing a specific antibody | |
CN110078820A (en) | Bovine leukemia virus antibody and detection kit | |
CN105085638A (en) | KSHV virus vIRF4 DNA binding domain and polyclonal antibody thereof, and preparation method of polyclonal antibody | |
CN117447561B (en) | Preparation and application of human papillomavirus type 16 E7 protein | |
CN118894915A (en) | A soluble chicken-derived PML protein and its efficient prokaryotic expression method and application | |
CN117843732A (en) | Linear B cell epitopes associated with African swine fever virus p30 protein and their application | |
CN105866435B (en) | The linear epitope minimum motif peptide Asp f 3 of aspergillus fumigatus Asp f 3123-127And its extension small peptide | |
CN117327166A (en) | A kind of chicken MFN1 antigenic determinant and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191008 |
|
RJ01 | Rejection of invention patent application after publication |